Literature DB >> 12181100

Genetic test evaluation: information needs of clinicians, policy makers, and the public.

Wylie Burke1, David Atkins, Marta Gwinn, Alan Guttmacher, James Haddow, Joseph Lau, Glenn Palomaki, Nancy Press, C Sue Richards, Louise Wideroff, Georgia L Wiesner.   

Abstract

Growing knowledge about gene-disease associations will lead to new opportunities for genetic testing. Many experts predict that genetic testing will become increasingly important as a guide to prevention, clinical management, and drug treatment based on genetic susceptibilities. As part of a Human Genetic Epidemiology workshop convened by the Centers for Disease Control and Prevention, a group of experts evaluated the evidence needed when considering the appropriate use of new genetic tests. Because new tests are likely to vary in their predictive value, their potential to direct prevention or treatment efforts, and their personal and social consequences, the task of determining appropriate use will require careful consideration of a variety of factors, including the analytic validity, clinical validity, clinical utility, and ethical, legal, and social implications of the test. Standardized formats are needed to summarize what is known and not known about new genetic tests with respect to each of these features. Following criteria for the objective assessment of test properties, reports should be structured to enable policy makers, clinicians, and the public to identify the available evidence, so that uncertainties can be taken into account when considering test use and planning future research.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181100     DOI: 10.1093/aje/kwf055

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  48 in total

1.  Direct-to-consumer sales of genetic services on the Internet.

Authors:  Sarah E Gollust; Benjamin S Wilfond; Sara Chandros Hull
Journal:  Genet Med       Date:  2003 Jul-Aug       Impact factor: 8.822

Review 2.  Criteria influencing the clinical uptake of pharmacogenomic strategies.

Authors:  Jai Shah
Journal:  BMJ       Date:  2004-06-19

3.  The EuroGentest clinical utility gene cards.

Authors:  Jörg Schmidtke; Jean-Jacques Cassiman
Journal:  Eur J Hum Genet       Date:  2010-09       Impact factor: 4.246

4.  Debating clinical utility.

Authors:  Wylie Burke; A-M Laberge; N Press
Journal:  Public Health Genomics       Date:  2010-04-15       Impact factor: 2.000

5.  Usefulness of factor V Leiden mutation testing in clinical practice.

Authors:  Ellen Ø Blinkenberg; Ann-Helen Kristoffersen; Sverre Sandberg; Vidar M Steen; Gunnar Houge
Journal:  Eur J Hum Genet       Date:  2010-03-24       Impact factor: 4.246

Review 6.  Health care policy issues as a result of the genetic revolution: implications for public health.

Authors:  Rohit P Ojha; Raymond Thertulien
Journal:  Am J Public Health       Date:  2005-03       Impact factor: 9.308

Review 7.  Genetics and public health--evolution, or revolution?

Authors:  Jane L Halliday; Veronica R Collins; Mary Anne Aitken; Martin P M Richards; Craig A Olsson
Journal:  J Epidemiol Community Health       Date:  2004-11       Impact factor: 3.710

8.  'Over-the-counter' genetic testing: what does it really mean for primary care?

Authors:  Imran Rafi; Nadeem Qureshi; Anneke Lucassen; Michael Modell; Frances Elmslie; Joe Kai; Maggie Kirk; Nigel Starey; Sheila Goff; Paul Brennan; Shirley Hodgson
Journal:  Br J Gen Pract       Date:  2009-04       Impact factor: 5.386

9.  Genetic tests: clinical validity and clinical utility.

Authors:  Wylie Burke
Journal:  Curr Protoc Hum Genet       Date:  2014-04-24

10.  Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening.

Authors:  Vikram Kilambi; F Reed Johnson; Juan Marcos González; Ateesha F Mohamed
Journal:  Value Health       Date:  2014-11-06       Impact factor: 5.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.